Vanguard Global Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.01M Buy
50,355
+2,398
+5% +$64.4K ﹤0.01% 1700
2026
Q2
$1.21M Sell
47,957
-1,776
-4% -$39.1K ﹤0.01% 1621
2026
Q1
$1.11M Buy
+49,733
New +$1.19M ﹤0.01% 1598

Other funds holding ACAD

Vanguard Global Advisers's ACAD Position: Q3 2026 in Review

Vanguard Global Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 5% in Q3 2026, buying an estimated $64.4K and bringing the position to 50,355 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1700.

Vanguard Global Advisers first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.21M in Q2 2026. 346 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Vanguard Global Advisers held 50,355 shares of Acadia Pharmaceuticals worth $1.01M as of Q3 2026.
  • Vanguard Global Advisers bought 2,398 Acadia Pharmaceuticals shares in Q3 2026, an estimated $64.4K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1700 holding.
  • Vanguard Global Advisers first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Acadia Pharmaceuticals position peaked at $1.21M in Q2 2026.
  • 346 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.